Pop Mart Shares Surge in Hong Kong After First Buyback in Nearly Two Years 
Trump Signs Executive Order to Limit Wall Street Investment in Single-Family Homes 
JPMorgan and Allen & Company Emerge as Big Winners in Warner Bros Discovery Bidding War 
United Airlines Posts Record Q4 Revenue as Premium Demand Lifts Earnings 
FSU Criticizes ANZ Over Suncorp Bank Job Cuts Amid Post-Acquisition Commitments 
FAA Says It Is Not Blocking Boeing 737 MAX 7 and MAX 10 Certification 
SoftBank Shares Surge as AI Optimism Lifts Asian Tech Stocks 
Intel Stock Slides Despite Earnings Beat as Weak Q1 Outlook Raises Concerns 
Court Allows Expert Testimony Linking Johnson & Johnson Talc Products to Ovarian Cancer 
ByteDance Finalizes Majority U.S.-Owned TikTok Joint Venture to Avert American Ban 
Baidu Shares Surge After Official Launch of Advanced Ernie 5.0 AI Model 
Nintendo Stock Jumps as Switch 2 Becomes Best-Selling Console in the U.S. in 2025 
BitGo IPO Prices Above Range, Raises $212.8M in Landmark Crypto Market Debut 
Netflix Stock Slips After Earnings as Soft 2026 Guidance Overshadows Subscriber Milestone 
Memory Chip Shortage Drives Higher Gadget Prices and Weakens Global Tech Demand 
Renault Group Global Sales Rise 3.2% in 2025 on Strong International and EV Demand 
ROCKVILLE, Md., May 02, 2017 -- REGENXBIO Inc. (Nasdaq:RGNX), a leading clinical-stage biotechnology company seeking to improve lives through the curative potential of gene therapy based on its proprietary NAV® Technology Platform, today announced that it will host a conference call on Tuesday, May 9, 2017 at 4:30 p.m. ET to discuss its financial results for the quarter ended March 31, 2017 and recent operational highlights.
To access the live call by phone, dial (855) 422-8964 (domestic) or (210) 229-8819 (international), and enter the passcode 13743533. To access a live or recorded webcast of the call, please visit the “Investors” section of the REGENXBIO website at www.regenxbio.com. The recorded webcast will be available for approximately 30 days following the call.
About REGENXBIO Inc.
REGENXBIO is a leading clinical-stage biotechnology company seeking to improve lives through the curative potential of gene therapy. REGENXBIO’s NAV® Technology Platform, a proprietary adeno-associated virus (AAV) gene delivery platform, consists of exclusive rights to more than 100 novel AAV vectors, including AAV7, AAV8, AAV9 and AAVrh10. REGENXBIO and its third-party NAV Technology Platform Licensees are applying the NAV Technology Platform in the development of a broad pipeline of product candidates in multiple therapeutic areas.
CONTACT: Investors Heather Savelle, 646-395-3734 [email protected] Media Adam Pawluk, 202-591-4063 [email protected]
